AU2018217809A1 - Benzothiophene estrogen receptor modulators - Google Patents
Benzothiophene estrogen receptor modulators Download PDFInfo
- Publication number
- AU2018217809A1 AU2018217809A1 AU2018217809A AU2018217809A AU2018217809A1 AU 2018217809 A1 AU2018217809 A1 AU 2018217809A1 AU 2018217809 A AU2018217809 A AU 2018217809A AU 2018217809 A AU2018217809 A AU 2018217809A AU 2018217809 A1 AU2018217809 A1 AU 2018217809A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- pct
- formula
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC*CCOc(cc1)ccc1-c1c(C(c(cc2)ccc2Cl)=O)[s]c2c1ccc(O)c2 Chemical compound CC*CCOc(cc1)ccc1-c1c(C(c(cc2)ccc2Cl)=O)[s]c2c1ccc(O)c2 0.000 description 38
- OWUTXBIONAXKAK-UHFFFAOYSA-N OCCN1CC(CF)C1 Chemical compound OCCN1CC(CF)C1 OWUTXBIONAXKAK-UHFFFAOYSA-N 0.000 description 2
- NEOIOGUWEUTYIH-UHFFFAOYSA-N C(C1)C2C1CNC2 Chemical compound C(C1)C2C1CNC2 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 description 1
- MSGFWOAOTSDHNS-UHFFFAOYSA-N C(COC1)C11CCCCC1 Chemical compound C(COC1)C11CCCCC1 MSGFWOAOTSDHNS-UHFFFAOYSA-N 0.000 description 1
- DGHSNWYCKFXXKF-AATRIKPKSA-N C/C=C/CC1CN(CCOc(cc2)ccc2Oc2c(C(c(c(C)c3)c(C)cc3F)=O)[s]c3cc(C)ccc23)C1 Chemical compound C/C=C/CC1CN(CCOc(cc2)ccc2Oc2c(C(c(c(C)c3)c(C)cc3F)=O)[s]c3cc(C)ccc23)C1 DGHSNWYCKFXXKF-AATRIKPKSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N C1NCC2C1CCCC2 Chemical compound C1NCC2C1CCCC2 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-GVHYBUMESA-N C1NCC2[C@@H]1CCCC2 Chemical compound C1NCC2[C@@H]1CCCC2 ODSNARDHJFFSRH-GVHYBUMESA-N 0.000 description 1
- SGKLCOPJOJKJKZ-UHFFFAOYSA-N CC(C=C1)=CC=CC1NSC Chemical compound CC(C=C1)=CC=CC1NSC SGKLCOPJOJKJKZ-UHFFFAOYSA-N 0.000 description 1
- BGVFDHDHPZBQKM-UHFFFAOYSA-N CC1CN(CCOc(cc2)ccc2-c2c(C(C(C(C)C3)=C(C)C=C3F)=O)[s]c3cc(O)ccc23)CC1 Chemical compound CC1CN(CCOc(cc2)ccc2-c2c(C(C(C(C)C3)=C(C)C=C3F)=O)[s]c3cc(O)ccc23)CC1 BGVFDHDHPZBQKM-UHFFFAOYSA-N 0.000 description 1
- NVKDPMFCXNPKMR-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c(c(C)c3)c(C)cc3Cl)=O)[s]c3c2ccc(O)c3)CC1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c(c(C)c3)c(C)cc3Cl)=O)[s]c3c2ccc(O)c3)CC1 NVKDPMFCXNPKMR-UHFFFAOYSA-N 0.000 description 1
- MGOXBQDDIXAFHR-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c(c(Cl)c3)ccc3F)=O)[s]c3cc(O)ccc23)CC1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c(c(Cl)c3)ccc3F)=O)[s]c3cc(O)ccc23)CC1 MGOXBQDDIXAFHR-UHFFFAOYSA-N 0.000 description 1
- FYHFUJIMPBPIMQ-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c3c(C)cc(C)cc3C)=O)[s]c3cc(O)ccc23)CC1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c3c(C)cc(C)cc3C)=O)[s]c3cc(O)ccc23)CC1 FYHFUJIMPBPIMQ-UHFFFAOYSA-N 0.000 description 1
- UAYNAOBSXBNWEE-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccc(C(F)(F)F)cc3)=O)[s]c3cc(O)ccc23)C1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccc(C(F)(F)F)cc3)=O)[s]c3cc(O)ccc23)C1 UAYNAOBSXBNWEE-UHFFFAOYSA-N 0.000 description 1
- XIZQYHGONYLACT-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccccc3C(F)(F)F)=O)[s]c3cc(O)ccc23)C1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccccc3C(F)(F)F)=O)[s]c3cc(O)ccc23)C1 XIZQYHGONYLACT-UHFFFAOYSA-N 0.000 description 1
- ZRXQYWPATXLREI-UHFFFAOYSA-N CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccccc3Cl)=O)[s]c3cc(O)ccc23)C1 Chemical compound CC1CN(CCc(cc2)ccc2Oc2c(C(c3ccccc3Cl)=O)[s]c3cc(O)ccc23)C1 ZRXQYWPATXLREI-UHFFFAOYSA-N 0.000 description 1
- WQEHGZMADMLWRI-UHFFFAOYSA-N CCC1CN(CCCOc(cc2)ccc2Oc2c(C(c(c(C)c3)ccc3Cl)=O)[s]c3cc(O)ccc23)C1 Chemical compound CCC1CN(CCCOc(cc2)ccc2Oc2c(C(c(c(C)c3)ccc3Cl)=O)[s]c3cc(O)ccc23)C1 WQEHGZMADMLWRI-UHFFFAOYSA-N 0.000 description 1
- CWYZDPHNAGSFQB-UHFFFAOYSA-N CCCCNCCC Chemical compound CCCCNCCC CWYZDPHNAGSFQB-UHFFFAOYSA-N 0.000 description 1
- YPLIAVPUGOJXMF-UHFFFAOYSA-N CCNCCOc(cc1)ccc1-c1c(C(c2c(C)ccc(Cl)c2)=O)[s]c2cc(O)ccc12 Chemical compound CCNCCOc(cc1)ccc1-c1c(C(c2c(C)ccc(Cl)c2)=O)[s]c2cc(O)ccc12 YPLIAVPUGOJXMF-UHFFFAOYSA-N 0.000 description 1
- UXJKPTDZIHIOJL-UHFFFAOYSA-N CCNCCOc(cc1)ccc1-c1c(C(c2ccc(C(F)(F)F)cc2)=O)[s]c2cc(O)ccc12 Chemical compound CCNCCOc(cc1)ccc1-c1c(C(c2ccc(C(F)(F)F)cc2)=O)[s]c2cc(O)ccc12 UXJKPTDZIHIOJL-UHFFFAOYSA-N 0.000 description 1
- CJTUEGGULOPGGV-UHFFFAOYSA-N CCNCCOc(cc1)ccc1-c1c(C(c2ccccc2)=O)[s]c2c1ccc(O)c2 Chemical compound CCNCCOc(cc1)ccc1-c1c(C(c2ccccc2)=O)[s]c2c1ccc(O)c2 CJTUEGGULOPGGV-UHFFFAOYSA-N 0.000 description 1
- YSIXDSNAXCLJEF-UHFFFAOYSA-N CCNCC[U]c(cc1)ccc1-c1c(C(c2c(C(F)(F)F)cccc2)=O)[s]c2cc(O)ccc12 Chemical compound CCNCC[U]c(cc1)ccc1-c1c(C(c2c(C(F)(F)F)cccc2)=O)[s]c2cc(O)ccc12 YSIXDSNAXCLJEF-UHFFFAOYSA-N 0.000 description 1
- KHIISKGVWHJMMF-UHFFFAOYSA-N CCNCC[U]c(cc1)ccc1-c1c(C(c2ccccc2C)=O)[s]c2c1ccc(O)c2 Chemical compound CCNCC[U]c(cc1)ccc1-c1c(C(c2ccccc2C)=O)[s]c2c1ccc(O)c2 KHIISKGVWHJMMF-UHFFFAOYSA-N 0.000 description 1
- FJRRZCTXKMCVOW-UHFFFAOYSA-N CCNCCc(cc1)ccc1Oc1c(C(c(c(Cl)c2)ccc2F)=O)[s]c2cc(C)ccc12 Chemical compound CCNCCc(cc1)ccc1Oc1c(C(c(c(Cl)c2)ccc2F)=O)[s]c2cc(C)ccc12 FJRRZCTXKMCVOW-UHFFFAOYSA-N 0.000 description 1
- WVGXMIZJLHGXMY-UHFFFAOYSA-N CCc1ccccc1C(c([s]c1cc(OC2C(C)CN(CCc(cc3)ccc3Oc3c(C(c(c(C)c4)c(C)cc4F)=O)[s]c4c3ccc(O)c4)C2)ccc11)c1Oc1ccc(CCN2CC(C)CC2)cc1)=O Chemical compound CCc1ccccc1C(c([s]c1cc(OC2C(C)CN(CCc(cc3)ccc3Oc3c(C(c(c(C)c4)c(C)cc4F)=O)[s]c4c3ccc(O)c4)C2)ccc11)c1Oc1ccc(CCN2CC(C)CC2)cc1)=O WVGXMIZJLHGXMY-UHFFFAOYSA-N 0.000 description 1
- ATAUHLOIQXTBRE-UHFFFAOYSA-N CN(C1CCCC1)SC Chemical compound CN(C1CCCC1)SC ATAUHLOIQXTBRE-UHFFFAOYSA-N 0.000 description 1
- NTMVMPJGYHZPIB-UHFFFAOYSA-N CN(CC1)CCC1C(F)F Chemical compound CN(CC1)CCC1C(F)F NTMVMPJGYHZPIB-UHFFFAOYSA-N 0.000 description 1
- WYFWXDSBNWLEDF-NRFANRHFSA-N C[C@@H]1CN(CCCc(cc2)ccc2Oc2c(C(c3ccc(C)cc3)=O)[s]c3cc(O)ccc23)CC1 Chemical compound C[C@@H]1CN(CCCc(cc2)ccc2Oc2c(C(c3ccc(C)cc3)=O)[s]c3cc(O)ccc23)CC1 WYFWXDSBNWLEDF-NRFANRHFSA-N 0.000 description 1
- NPPCSVKZEKXANP-SFHVURJKSA-N C[C@@H]1CN(CCOc(cc2)ccc2Oc2c(C(c(cc3)ccc3F)=O)[s]c3cc(O)ccc23)CC1 Chemical compound C[C@@H]1CN(CCOc(cc2)ccc2Oc2c(C(c(cc3)ccc3F)=O)[s]c3cc(O)ccc23)CC1 NPPCSVKZEKXANP-SFHVURJKSA-N 0.000 description 1
- YWJSZSDEJJANCM-IBGZPJMESA-N C[C@@H]1CN(CCOc(cc2)ccc2Oc2c(C(c3ccccc3)=O)[s]c3cc(O)ccc23)CC1 Chemical compound C[C@@H]1CN(CCOc(cc2)ccc2Oc2c(C(c3ccccc3)=O)[s]c3cc(O)ccc23)CC1 YWJSZSDEJJANCM-IBGZPJMESA-N 0.000 description 1
- AQOALAYNWDQSLT-UHFFFAOYSA-N Cc(cc1)ccc1C(c([s]c1cc(O)ccc11)c1Oc1ccc(CCN(C2)CC2C(F)F)cc1)=O Chemical compound Cc(cc1)ccc1C(c([s]c1cc(O)ccc11)c1Oc1ccc(CCN(C2)CC2C(F)F)cc1)=O AQOALAYNWDQSLT-UHFFFAOYSA-N 0.000 description 1
- SKTDQZIZRBMZKD-UHFFFAOYSA-N Cc1cc(Cl)ccc1C(c([s]c1c2ccc(O)c1)c2-c(cc1)ccc1OCCN1CC(CF)C1)=O Chemical compound Cc1cc(Cl)ccc1C(c([s]c1c2ccc(O)c1)c2-c(cc1)ccc1OCCN1CC(CF)C1)=O SKTDQZIZRBMZKD-UHFFFAOYSA-N 0.000 description 1
- IGTUDBGZILUJES-UHFFFAOYSA-N Cc1cc(F)ccc1C(c([s]c1c2ccc(O)c1)c2-c(cc1)ccc1OCCN1CC(CF)C1)=O Chemical compound Cc1cc(F)ccc1C(c([s]c1c2ccc(O)c1)c2-c(cc1)ccc1OCCN1CC(CF)C1)=O IGTUDBGZILUJES-UHFFFAOYSA-N 0.000 description 1
- YRWIHLZRZOLWDA-UHFFFAOYSA-N Cc1ccccc1C(c([s]c1c2ccc(O)c1)c2Oc1ccc(CCN(C2)CC2C(F)F)cc1)=O Chemical compound Cc1ccccc1C(c([s]c1c2ccc(O)c1)c2Oc1ccc(CCN(C2)CC2C(F)F)cc1)=O YRWIHLZRZOLWDA-UHFFFAOYSA-N 0.000 description 1
- HVLHBOZRBDEOLH-UHFFFAOYSA-N Cc1ccccc1C(c([s]c1cc(O)ccc11)c1-c(cc1)ccc1OCCCN1CC(CF)C1)=O Chemical compound Cc1ccccc1C(c([s]c1cc(O)ccc11)c1-c(cc1)ccc1OCCCN1CC(CF)C1)=O HVLHBOZRBDEOLH-UHFFFAOYSA-N 0.000 description 1
- GALQXSNDABDPNV-UHFFFAOYSA-N Oc(cc1)cc2c1c(-c(cc1)ccc1OCCCN1CC(CF)C1)c(C(c1ccccc1)=O)[s]2 Chemical compound Oc(cc1)cc2c1c(-c(cc1)ccc1OCCCN1CC(CF)C1)c(C(c1ccccc1)=O)[s]2 GALQXSNDABDPNV-UHFFFAOYSA-N 0.000 description 1
- IOCLIBCVOLGGPF-UHFFFAOYSA-N Oc1ccc2c(Oc3ccc(CCN(C4)CC4C(F)F)cc3)c(C(c3ccccc3)=O)[s]c2c1 Chemical compound Oc1ccc2c(Oc3ccc(CCN(C4)CC4C(F)F)cc3)c(C(c3ccccc3)=O)[s]c2c1 IOCLIBCVOLGGPF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762457643P | 2017-02-10 | 2017-02-10 | |
US62/457,643 | 2017-02-10 | ||
US201762460358P | 2017-02-17 | 2017-02-17 | |
US62/460,358 | 2017-02-17 | ||
US201862614279P | 2018-01-05 | 2018-01-05 | |
US62/614,279 | 2018-01-05 | ||
PCT/US2018/017668 WO2018148576A1 (en) | 2017-02-10 | 2018-02-09 | Benzothiophene estrogen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2018217809A1 true AU2018217809A1 (en) | 2019-08-22 |
Family
ID=63106724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018217809A Abandoned AU2018217809A1 (en) | 2017-02-10 | 2018-02-09 | Benzothiophene estrogen receptor modulators |
Country Status (10)
Country | Link |
---|---|
US (3) | US10208011B2 (zh) |
EP (1) | EP3580223A4 (zh) |
JP (1) | JP2020507566A (zh) |
KR (1) | KR20190117582A (zh) |
CN (1) | CN110461853A (zh) |
AU (1) | AU2018217809A1 (zh) |
CA (1) | CA3052810A1 (zh) |
IL (1) | IL268319A (zh) |
TW (1) | TW201835064A (zh) |
WO (1) | WO2018148576A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968291A4 (en) | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | HSPC-PROOF TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION |
WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
JP7348665B2 (ja) * | 2018-02-06 | 2023-09-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 |
CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
CA3109385A1 (en) * | 2018-08-16 | 2020-02-20 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators to treat medical disorders |
CN114761082A (zh) | 2019-09-30 | 2022-07-15 | 日本化学药品株式会社 | 氮杂环庚烷衍生物 |
CN115698014A (zh) | 2020-05-19 | 2023-02-03 | G1治疗公司 | 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物 |
CN113816892A (zh) * | 2021-08-27 | 2021-12-21 | 安徽鼎旺医药有限公司 | 一种醋酸巴多昔芬的合成方法 |
CN113801094A (zh) * | 2021-10-29 | 2021-12-17 | 中国药科大学 | 一种2-羰基苯并噻吩类化合物及其制备方法和用途 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU509682B2 (en) | 1975-10-28 | 1980-05-22 | Eli Lilly And Company | 2-Aroyl-3-Phenylbenzothiophene Derivatives |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
EP0146243A1 (en) | 1983-10-31 | 1985-06-26 | Merck Frosst Canada Inc. | Lipoxygenase inhibitors |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
AU9399898A (en) | 1997-10-03 | 1999-04-27 | Eli Lilly And Company | Benzothiophenes |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
US6060488A (en) * | 1998-09-22 | 2000-05-09 | Eli Lilly And Company | Benzothiophenes for treating estrogen deficiency |
CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
WO2002003990A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted insole compounds for treating excessive intraocular pressure |
AU2001271781A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
US20020016318A1 (en) | 2000-07-06 | 2002-02-07 | American Home Products Corporation | Methods of treating breast disorders |
AU2001273074A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Combinations of ssri and estrogenic agents |
WO2002003992A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating prosthesis-related bone degeneration |
US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
EP1299093A2 (en) | 2000-07-06 | 2003-04-09 | Wyeth | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
MXPA02012896A (es) | 2000-07-06 | 2003-10-24 | Wyeth Corp | Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. |
US20020022617A1 (en) | 2000-07-06 | 2002-02-21 | American Home Products Corporation | Methods for increasing nitric oxide synthase activity |
ATE278421T1 (de) | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
EP1664052B1 (en) | 2003-08-15 | 2009-02-18 | AstraZeneca AB | Fused heterocycles as inhibitors of glutamate racemase (muri) |
FR2862646B1 (fr) | 2003-11-20 | 2006-02-24 | Merck Sante Sas | Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes |
WO2006078834A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
US8278290B2 (en) | 2005-02-14 | 2012-10-02 | Biononics Limited | Tubulin polymerisation inhibitors |
NZ570014A (en) | 2006-02-03 | 2011-04-29 | Bionomics Ltd | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
EP2037905B1 (en) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
EP1947085A1 (en) | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
BRPI0814532A2 (pt) | 2007-07-25 | 2015-01-27 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos. |
WO2010093578A1 (en) | 2009-02-10 | 2010-08-19 | Glaxo Group Limited | Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors |
US8809382B2 (en) | 2009-05-04 | 2014-08-19 | The Royal Institution For The Advancement Of Learning/Mcgill University | 5-oxo-ETE receptor antagonist compounds |
EP2580210B1 (en) | 2010-06-10 | 2017-03-01 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
JP5886873B2 (ja) | 2010-12-24 | 2016-03-16 | メルク・シャープ・エンド・ドーム・ベー・フェー | N置換アゼチジン誘導体 |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
MD20140054A2 (ro) | 2011-12-16 | 2014-10-31 | Olema Pharmaceuticals, Inc. | Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora |
KR20140117457A (ko) | 2012-01-31 | 2014-10-07 | 노파르티스 아게 | Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도 |
WO2013142266A1 (en) | 2012-03-20 | 2013-09-26 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2014066695A1 (en) | 2012-10-24 | 2014-05-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating estrogen-related medical disorders |
US9475791B2 (en) | 2012-10-24 | 2016-10-25 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating estrogen-related medical disorders |
AU2014219283C1 (en) | 2013-02-19 | 2016-10-27 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
JP2016517420A (ja) | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ, インク. | 多環式エストロゲン受容体モジュレーター及びその使用 |
PT3004090T (pt) | 2013-05-28 | 2017-12-22 | Astrazeneca Ab | Compostos químicos |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
KR20160021277A (ko) | 2013-06-19 | 2016-02-24 | 세라곤 파마슈티컬스, 인크. | 에스트로겐 수용체 조절제 및 이의 용도 |
GB201311888D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
MX2016011636A (es) | 2014-03-13 | 2016-12-12 | Hoffmann La Roche | Combinaciones terapeuticas con moduladores de receptor de estrogeno. |
EP3116496A1 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Methods and compositions for modulating estrogen receptor mutants |
LT3122426T (lt) | 2014-03-28 | 2023-03-10 | Duke University | Krūties vėžio gydymas, naudojant selektyvius estrogenų receptorių moduliatorius |
CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
AU2016331065B2 (en) | 2015-10-01 | 2021-04-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido(3,4-b)indole anti-estrogenic drugs |
WO2017056115A1 (en) | 2015-10-03 | 2017-04-06 | Sun Pharma Advanced Research Company Limited | Novel n-aryl containing fused heterocyclic compounds |
JP2018533561A (ja) | 2015-10-07 | 2018-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | (e)−3−(4−((e)−2−(2−クロロ−4−フルオロフェニル)−1−(1h−インダゾール−5−イル)ブタ−1−エン−1−イル)フェニル)アクリル酸を調製するためのプロセス |
IL283559B (en) | 2015-10-27 | 2022-07-01 | Sun Pharma Advanced Res Co Ltd | New heterocyclic anti-estrogens |
EP3386968A4 (en) | 2015-12-09 | 2019-09-25 | The Board of Trustees of the University of Illinois | BENZOTHIOPHEN-BASED SELECTIVE ESTROGEN RECEPTOR-DOWN-REGULATING PREPARATIONS |
EP3416962B1 (en) | 2016-02-15 | 2021-05-05 | Sanofi | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators |
-
2018
- 2018-02-09 AU AU2018217809A patent/AU2018217809A1/en not_active Abandoned
- 2018-02-09 CN CN201880020916.XA patent/CN110461853A/zh active Pending
- 2018-02-09 CA CA3052810A patent/CA3052810A1/en not_active Abandoned
- 2018-02-09 JP JP2019542672A patent/JP2020507566A/ja not_active Withdrawn
- 2018-02-09 EP EP18751944.2A patent/EP3580223A4/en not_active Withdrawn
- 2018-02-09 KR KR1020197026068A patent/KR20190117582A/ko unknown
- 2018-02-09 US US15/893,295 patent/US10208011B2/en not_active Expired - Fee Related
- 2018-02-09 WO PCT/US2018/017668 patent/WO2018148576A1/en unknown
- 2018-02-09 TW TW107104795A patent/TW201835064A/zh unknown
- 2018-12-14 US US16/221,201 patent/US10633362B2/en not_active Expired - Fee Related
-
2019
- 2019-07-29 IL IL268319A patent/IL268319A/en unknown
-
2020
- 2020-03-19 US US16/824,290 patent/US10981887B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2020507566A (ja) | 2020-03-12 |
US10633362B2 (en) | 2020-04-28 |
KR20190117582A (ko) | 2019-10-16 |
US20200216406A1 (en) | 2020-07-09 |
TW201835064A (zh) | 2018-10-01 |
US10208011B2 (en) | 2019-02-19 |
WO2018148576A1 (en) | 2018-08-16 |
US20180230123A1 (en) | 2018-08-16 |
CA3052810A1 (en) | 2018-08-16 |
EP3580223A4 (en) | 2021-01-06 |
CN110461853A (zh) | 2019-11-15 |
EP3580223A1 (en) | 2019-12-18 |
US20190119243A1 (en) | 2019-04-25 |
US10981887B2 (en) | 2021-04-20 |
IL268319A (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10981887B2 (en) | Benzothiophene estrogen receptor modulators | |
US11072595B2 (en) | Benzothiophene-based selective estrogen receptor downregulator compounds | |
US20210171554A1 (en) | Benzothiophene estrogen receptor modulators to treat medical disorders | |
US10703747B2 (en) | Benzothiophene-based selective mixed estrogen receptor downregulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |